Introduction: Central precocious puberty (CPP) is the premature activation of the hypothalamic-pituitary-gonadal axis, often compromising adult height and psychosocial well-being. Timely treatment with gonadotropin-releasing hormone agonists (GnRHa) such as triptorelin is critical to halt pubertal progression and preserve growth potential. This study evaluated the clinical outcomes of triptorelin therapy in CPP at Sarawak General Hospital (SGH). Methodology: A retrospective cross-sectional study was conducted among patients with CPP treated with triptorelin at the Paediatric Endocrine Clinic, SGH, including those currently receiving therapy and those who had discontinued treatment. Demographic and clinical data were extracted from medical records and analyzed using SPSS version 25. Descriptive statistics summarized patient characteristics, while t-tests and non-parametric equivalents assessed treatment outcomes (p <0.05 significant). Results: Eleven patients were included (mean age 6.88 ± 2.21 years; 90.9% female). Two patients (18.2%) were obese at initial diagnosis, and the mean baseline body mass index was 17.64 ± 2.25 kg/m². Most cases were idiopathic (54.5%), while pituitary microadenoma was identified in 36.4%. At diagnosis, the bone age was advanced by a mean of 3.51 ± 1.39 years. Six patients discontinued therapy: four after completion and two at parental request. Among completers, mean treatment duration was 3.21 ± 2.42 years, ending at a mean age of 10.13 ± 0.95 years. Final height did not differ significantly from mid-parental height (p = 0.225). Triptorelin significantly improved final height standard deviation score (SDS) (p = 0.005) and reduced the bone age/ chronological age ratio (p = 0.049), though predicted adult height gains were not statistically significant (p = 0.321). No adverse effects were reported. Conclusion GnRHa therapy slowed pubertal progression and preserved growth potential in children with CPP, with favorable safety outcomes. Larger prospective studies are warranted to validate long-term benefits and identify predictors of optimal response.
Child ; Puberty, Precocious ; Gonadotropin-Releasing Hormone